{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:23:48Z","timestamp":1791296628669,"version":"4.1.0"},"reference-count":62,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,1,5]]},"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with chemotherapy-induced thrombocytopaenia frequently experience minor and sometimes severe bleeding complications. Unrestrictive availability of safe and effective blood products is presumed by treating physicians as well as patients. Pathogen reduction technology potentially offers the opportunity to enhance safety by reducing bacterial and viral contamination of platelet products along with a potential reduction of alloimmunisation in patients receiving multiple platelet transfusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>To test efficacy, a randomised, single-blinded, multicentre controlled trial was designed to evaluate clinical non-inferiority of pathogen-reduced platelet concentrates treated by the Mirasol system, compared with standard plasma-stored platelet concentrates using the percentage of patients with WHO grade \u22652 bleeding complications as the primary endpoint. The upper limit of the 95% CI of the non-inferiority margin was chosen to be a \u226412.5% increase in this percentage. Bleeding symptoms are actively monitored on a daily basis. The adjudication of the bleeding grade is performed by 3 adjudicators, blinded to the platelet product randomisation as well as by an automated computer algorithm. Interim analyses evaluating bleeding complications as well as serious adverse events are performed after each batch of 60 patients. The study started in 2010 and patients will be enrolled up to a maximum of 618 patients, depending on the results of consecutive interim analyses. A flexible stopping rule was designed allowing stopping for non-inferiority or futility. Besides analysing effects of pathogen reduction on clinical efficacy, the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) is designed to answer several other pending questions and translational issues related to bleeding and alloimmunisation, formulated as secondary and tertiary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained in all 3 participating countries. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NTR2106; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010156","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T22:34:22Z","timestamp":1453934062000},"page":"e010156","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial"],"prefix":"10.1136","volume":"6","author":[{"given":"Paula F","family":"Ypma","sequence":"first","affiliation":[{"name":"Department of Hematology, HAGA Teaching Hospital Den Haag, The Netherlands"},{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter F","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M","family":"Heddle","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Department of Medicine, Canadian Blood Services, McMaster University, and Centre for Innovation, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost A","family":"van Hilten","sequence":"additional","affiliation":[{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Stijnen","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger A","family":"Middelburg","sequence":"additional","affiliation":[{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Hervig","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, and Department of Clinical Science, Haukeland University Hospital, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna G","family":"van der Bom","sequence":"additional","affiliation":[{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Brand","sequence":"additional","affiliation":[{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis H","family":"Kerkhoffs","sequence":"additional","affiliation":[{"name":"Department of Hematology, HAGA Teaching Hospital Den Haag, The Netherlands"},{"name":"Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"2025121300175840000_6.1.e010156.1","first-page":"94","article-title":"Bleeding complications in patients with hematologic malignancies","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2025121300175840000_6.1.e010156.2","unstructured":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/transcripts\/2004\u20134057t1.htm"},{"key":"2025121300175840000_6.1.e010156.3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1537-2995.2003.030342.x","article-title":"Bacterial contamination of blood: lessons from the past and road map for the future","volume":"44","author":"Yomtovian","year":"2004","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1537-2995.2002.00147.x","article-title":"Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study","volume":"42","author":"Dumont","year":"2002","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1537-2995.2003.00622.x","article-title":"In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days","volume":"44","author":"Dijkstra-Tiekstra","year":"2004","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01221.x"},{"key":"2025121300175840000_6.1.e010156.7","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-25"},{"key":"2025121300175840000_6.1.e010156.8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.transci.2014.12.016","article-title":"Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands","volume":"52","author":"Salunkhe","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"2025121300175840000_6.1.e010156.9","doi-asserted-by":"crossref","unstructured":"Butler C , Doree C , Estcourt LJ , et al . Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013;(3):CD009072. doi:10.1002\/14651858.CD009072.pub2","DOI":"10.1002\/14651858.CD009072.pub2"},{"key":"2025121300175840000_6.1.e010156.10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/vox.12098","article-title":"Bacterial contamination in platelet concentrates","volume":"106","author":"Pietersz","year":"2014","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1423-0410.2004.00548.x","article-title":"Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products","volume":"87","author":"Li","year":"2004","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03355.x"},{"key":"2025121300175840000_6.1.e010156.13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1537-2995.2009.02126.x","article-title":"A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns","volume":"49","author":"Goodrich","year":"2009","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.14","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1537-2995.2010.02694.x","article-title":"A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology","volume":"50","author":"Mirasol Clinical Evaluation Study Group","year":"2010","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.15","first-page":"1861","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group","volume":"37","year":"1997","journal-title":"N Engl J Med"},{"key":"2025121300175840000_6.1.e010156.16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijerph8010015","article-title":"Blocked randomization with randomly selected block sizes","volume":"8","author":"Efird","year":"2011","journal-title":"Int J Environ Res Public Health"},{"key":"2025121300175840000_6.1.e010156.17","doi-asserted-by":"publisher","DOI":"10.2307\/2965404"},{"key":"2025121300175840000_6.1.e010156.18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.0042-9007.2001.00104.x","article-title":"Evaluation of the BacT\/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates","volume":"81","author":"McDonald","year":"2001","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4443"},{"key":"2025121300175840000_6.1.e010156.20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1537-2995.2005.00671.x","article-title":"Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light","volume":"46","author":"Murphy","year":"2006","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.21","unstructured":"CBO, Kwaliteitsinstituut voor de Gezondheidszorg. Richtlijn Bloedtransfusie. Utrecht, 2004. http:\/\/nvic.nl\/sites\/default\/files\/CBO%20Richtlijn%20Bloedtransfusie.pdf"},{"key":"2025121300175840000_6.1.e010156.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.03.003"},{"key":"2025121300175840000_6.1.e010156.23","doi-asserted-by":"publisher","DOI":"10.1053\/tmrv.2002.29403"},{"key":"2025121300175840000_6.1.e010156.24","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12058"},{"key":"2025121300175840000_6.1.e010156.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178236"},{"key":"2025121300175840000_6.1.e010156.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904084"},{"key":"2025121300175840000_6.1.e010156.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212772"},{"key":"2025121300175840000_6.1.e010156.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60689-8"},{"key":"2025121300175840000_6.1.e010156.29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-3148.2012.01193.x","article-title":"The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting","volume":"22","author":"Ypma","year":"2012","journal-title":"Transfus Med"},{"key":"2025121300175840000_6.1.e010156.30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V66.5.1105.1105","article-title":"Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement","volume":"66","author":"Hanson","year":"1985","journal-title":"Blood"},{"key":"2025121300175840000_6.1.e010156.31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1423-0410.2006.00761.x","article-title":"Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects","volume":"90","author":"Goodrich","year":"2006","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501247"},{"key":"2025121300175840000_6.1.e010156.33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1423-0410.2009.01283.x","article-title":"In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system","volume":"98","author":"van der Meer","year":"2010","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1537-2995.1991.31591263195.x","article-title":"Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion","volume":"31","author":"Rinder","year":"1991","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11877"},{"key":"2025121300175840000_6.1.e010156.36","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V92.11.4446","article-title":"P-selectin and platelet clearance","volume":"92","author":"Berger","year":"1998","journal-title":"Blood"},{"key":"2025121300175840000_6.1.e010156.37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1537-2995.2004.04042.x","article-title":"Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates","volume":"44","author":"Leytin","year":"2004","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0037-1613103","article-title":"Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs","volume":"87","author":"Pereira","year":"2002","journal-title":"Thromb Haemost"},{"key":"2025121300175840000_6.1.e010156.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00670.x"},{"key":"2025121300175840000_6.1.e010156.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(01)00239-1"},{"key":"2025121300175840000_6.1.e010156.41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1423-0410.1993.tb02147.x","article-title":"Role of lactate in platelet storage lesion","volume":"65","author":"Bertolini","year":"1993","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.42","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/j.1537-2995.2009.02302.x","article-title":"Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies","volume":"49","author":"Maurer-Spurej","year":"2009","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.43","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000287318.94088.d7"},{"key":"2025121300175840000_6.1.e010156.44","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/j.1537-2995.2010.02714.x","article-title":"White blood cell inactivation after treatment with riboflavin and ultraviolet light","volume":"50","author":"Marschner","year":"2010","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.45","doi-asserted-by":"crossref","unstructured":"Slichter SJ , Pellham E , Lawrence Bailey S , et al . Filtration leukoreduction followed by pathogen-reduction (Mirasol Treatment) prevents alloimmune platelet refractoriness in a dog platelet transfusion model [abstract]. Blood 2012;120:Abstract 271.","DOI":"10.1182\/blood.V120.21.271.271"},{"key":"2025121300175840000_6.1.e010156.46","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/j.1537-2995.2009.02333.x","article-title":"Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment","volume":"49","author":"Jackman","year":"2009","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.47","first-page":"517","article-title":"Functional inactivation of white blood cells by Mirasol treatment","volume":"98","author":"Fast","year":"2010","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.48","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1537-2995.2010.02589.x","article-title":"Identification of specificities of antibodies against human leukocyte antigens in blood donors","volume":"50","author":"Endres","year":"2010","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1139\/Y07-045","article-title":"Vascular endothelium: target or victim of cytostatic therapy?","volume":"85","author":"Romanov","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"key":"2025121300175840000_6.1.e010156.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2004.05.003"},{"key":"2025121300175840000_6.1.e010156.51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1099800405286138","article-title":"Cytosine arabinoside induces programmed endothelial cell death through the caspase-3 pathway","volume":"7","author":"Moore","year":"2006","journal-title":"Biol Res Nurs"},{"key":"2025121300175840000_6.1.e010156.52","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra0800887","article-title":"Platelets, petechiae, and preservation of the vascular wall","volume":"359","author":"Nachman","year":"2009","journal-title":"N Engl J Med"},{"key":"2025121300175840000_6.1.e010156.53","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181a4158c"},{"key":"2025121300175840000_6.1.e010156.54","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0961-8"},{"key":"2025121300175840000_6.1.e010156.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068178"},{"key":"2025121300175840000_6.1.e010156.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02699.x"},{"key":"2025121300175840000_6.1.e010156.57","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1537-2995.2006.00999.x","article-title":"A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms","volume":"46","author":"Webert","year":"2006","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/vox.12030","article-title":"Measuring clinical bleeding using a standardized daily report form and a computer algorithm for adjudication of WHO bleeding grades","volume":"105","author":"Middelburg","year":"2013","journal-title":"Vox Sang"},{"key":"2025121300175840000_6.1.e010156.59","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/trf.13030","article-title":"Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment","volume":"55","author":"Keil","year":"2015","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.60","first-page":"1530","article-title":"The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia","volume":"91","author":"Webert","year":"2006","journal-title":"Haematologica"},{"key":"2025121300175840000_6.1.e010156.61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1537-2995.2010.02982.x","article-title":"Time to rethink clinically important outcomes in platelet transfusion trials","volume":"51","author":"Heddle","year":"2011","journal-title":"Transfusion"},{"key":"2025121300175840000_6.1.e010156.62","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1537-2995.2012.03634.x","article-title":"A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia","volume":"52","author":"Webert","year":"2012","journal-title":"Transfusion"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:18:06Z","timestamp":1765613886000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,27]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1136\/bmjopen-2015-010156"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010156","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}